BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25174598)

  • 21. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The aspirin controversy in primary prevention.
    Raju NC; Eikelboom JW
    Curr Opin Cardiol; 2012 Sep; 27(5):499-507. PubMed ID: 22874127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Aspirin in primary prevention of cardiovascular diseases: how to balance risks and benefits].
    De Caterina R; Orlando D; Berti V; Coccheri S
    G Ital Cardiol (Rome); 2012; 13(7-8):494-502. PubMed ID: 22781376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.
    Prescrire Int; 2010 Nov; 19(110):258-61. PubMed ID: 21284360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary prevention of cardiovascular complications in type II diabetes patients using aspirin: a complicated tale.
    Schmidt BM; Arora R
    Am J Ther; 2013; 20(3):275-8. PubMed ID: 19797944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
    Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
    Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study.
    Lin KJ; De Caterina R; García Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):70-7. PubMed ID: 24254886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
    Sandler RS
    Important Adv Oncol; 1996; ():123-37. PubMed ID: 8791132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AAA- a further step towards a moratorium for aspirin in the primary prevention.
    Minar E
    Vasa; 2010 May; 39(2):119-122. PubMed ID: 20521434
    [No Abstract]   [Full Text] [Related]  

  • 33. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
    Hennekens CH; Sechenova O; Hollar D; Serebruany VL
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose aspirin for everyone?
    Johns Hopkins Med Lett Health After 50; 2002 Oct; 14(8):4-5. PubMed ID: 12425276
    [No Abstract]   [Full Text] [Related]  

  • 35. Aspirin in primary prevention of cardiovascular disease in the elderly.
    Galli M; Andreotti F; D'Amario D; Vergallo R; Montone RA; Porto I; Crea F
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):326-327. PubMed ID: 31504373
    [No Abstract]   [Full Text] [Related]  

  • 36. Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study.
    Selak V; Jackson R; Poppe K; Wu B; Harwood M; Grey C; Pylypchuk R; Mehta S; Kerr A; Wells S
    Ann Intern Med; 2019 Mar; 170(6):357-368. PubMed ID: 30802900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin in the primary prevention of cardiovascular disease.
    Hennekens CH; Buring JE
    Cardiol Clin; 1994 Aug; 12(3):443-50. PubMed ID: 7805078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
    Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Primary prevention of cardiovascular disease with acetylsalicylic acid: in high-risk patients].
    Kappelle LJ
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):853-4. PubMed ID: 15868987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aspirin for primary prevention of cardiovascular disease?
    Drug Ther Bull; 2009 Nov; 47(11):122-5. PubMed ID: 19887685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.